Regulatory T Cells and Transplantation Tolerance

Human Immunology

Volumn 67, Issue 10, 2006, Pages 765-776

  Jiang, Shuiping ^a   Lechler, Robert I ^a   He, Xiao Shun ^b   Huang, Jie Fu ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

T cells; adoptive cell therapy; anergic CD4+ T cells; CD3+CD4 CD8 T cells; CD4+CD25+ Tregs; CD8+CD28 T cells; FoxP3; indirect allospecificity; individualized medicine; NKT cells; Regulatory T cells; Th3; Tr1; transplantation tolerance

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 33750008921     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2006.07.013     Document Type: Review

References (145)

1. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., and Toda M. Immunologic self-tolerance maintained by activated T cel.ls expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151
2. Asano M., Toda M., Sakaguchi N., and Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med 184 (1996) 387
3. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345
4. Hall B.M., Pearce N.W., Gurley K.E., and Dorsch S.E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J Exp Med 171 (1990) 141
5. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A.R., Morris P.J., Powrie F., and Wood K.J. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 166 (2001) 3789
6. Taylor P.A., Noelle R.J., and Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 193 (2001) 1311
7. Gregori S., Casorati M., Amuchastegui S., Smiroldo S., Davalli A.M., and Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167 (2001) 1945
8. Sanchez-Fueyo A., Weber M., Domenig C., Strom T.B., and Zheng X.X. Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol 168 (2002) 2274
9. Zheng X.X., Sanchez-Fueyo A., Sho M., Domenig C., Sayegh M.H., and Strom T.B. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 19 (2003) 503
10. Adeegbe D., Bayer A.L., Levy R.B., and Malek T.R. Allogeneic CD4+CD25+Foxp3+ T Regulatory cells suppress autoimmunity while establishing transplantation tolerance. J Immunol 176 (2006) 7149
11. Ochando J.C., Homma C., Yang Y., Hidalgo A., Garin A., Tacke F., Angeli V., Li Y., Boros P., Ding Y., Jessberger R., Trinchieri G., Lira S.A., Randolph G.J., and Bromberg J.S. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 7 (2006) 652
12. Graca L., Cobbold S.P., and Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 195 (2002) 1641
13. Jiang S., and Lechler R.I. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant 3 (2003) 516
14. Jiang S., Herrera O., and Lechler R.I. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol 16 (2004) 550
15. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199
16. Waldmann H., and Cobbold S. Exploiting tolerance processes in transplantation. Science 305 (2004) 209
17. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23 (2005) 877
18. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., and Roncarolo M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737
19. Faria A.M., and Weiner H.L. Oral tolerance. Immunol Rev 206 (2005) 232
20. Schwartz R.H. T cell anergy. Annu Rev Immunol 21 (2003) 305
21. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., Lederman S., Colonna M., Cortesini R., Dalla-Favera R., and Suciu-Foca N. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 (2002) 237
22. Zhang Z.X., Yang L., Young K.J., DuTemple B., and Zhang L. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 6 (2000) 782
23. Hayday A., and Tigelaar R. Immunoregulation in the tissues by gammadelta T cells. Nat Rev Immunol 3 (2003) 233
24. Zhou D., Mattner J., Cantu III C., Schrantz N., Yin N., Gao Y., Sagiv Y., Hudspeth K., Wu Y.P., Yamashita T., Teneberg S., Wang D., Proia R.L., Levery S.B., Savage P.B., Teyton L., and Bendelac A. Lysosomal glycosphingolipid recognition by NKT cells. Science 306 (2004) 1786
25. Mattner J., Debord K.L., Ismail N., Goff R.D., Cantu III C., Zhou D., Saint-Mezard P., Wang V., Gao Y., Yin N., Hoebe K., Schneewind O., Walker D., Beutler B., Teyton L., Savage P.B., and Bendelac A. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 (2005) 525
26. Kinjo Y., Wu D., Kim G., Xing G.W., Poles M.A., Ho D.D., Tsuji M., Kawahara K., Wong C.H., and Kronenberg M. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434 (2005) 520
27. Benlagha K., Kyin T., Beavis A., Teyton L., and Bendelac A. A thymic precursor to the NK T cell lineage. Science 296 (2002) 553
28. Pellicci D.G., Hammond K.J., Uldrich A.P., Baxter A.G., Smyth M.J., and Godfrey D.I. A natural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. J Exp Med 195 (2002) 835
29. Van Kaer L. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat Rev Immunol 5 (2005) 31
30. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., Miura T., Haba T., Scherer D.C., Wei J., Kronenberg M., Koezuka Y., and Van Kaer L. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7 (2001) 1052
31. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., Kronenberg M., Koezuka Y., Delovitch T.L., Gombert J.M., Leite-De-Moraes M., Gouarin C., Zhu R., Hameg A., Nakayama T., Taniguchi M., Lepault F., Lehuen A., Bach J.F., and Herbelin A. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7 (2001) 1057
32. Miyamoto K., Miyake S., and Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 (2001) 531
33. Singh A.K., Wilson M.T., Hong S., Olivares-Villagomez D., Du C., Stanic A.K., Joyce S., Sriram S., Koezuka Y., and Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 194 (2001) 1801
34. Zeng D., Lee M.K., Tung J., Brendolan A., and Strober S. A role for CD1 in the pathogenesis of lupus in NZB/NZW mice. J Immunol 164 (2000) 5000
35. Wilson S.B., Kent S.C., Patton K.T., Orban T., Jackson R.A., Exley M., Porcelli S., Schatz D.A., Atkinson M.A., Balk S.P., Strominger J.L., and Hafler D.A. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391 (1998) 177
36. Lee P.T., Putnam A., Benlagha K., Teyton L., Gottlieb P.A., and Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110 (2002) 793
37. Sumida T., Sakamoto A., Murata H., Makino Y., Takahashi H., Yoshida S., Nishioka K., Iwamoto I., and Taniguchi M. Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med 182 (1995) 1163
38. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., and Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1 (2000) 515
39. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., Nakayama T., Taniguchi M., Koezuka Y., and Tsuji M. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195 (2002) 617
40. Zeng D., Lewis D., Dejbakhsh-Jones S., Lan F., Garcia-Ojeda M., Sibley R., and Strober S. Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 189 (1999) 1073
41. Haraguchi K., Takahashi T., Matsumoto A., Asai T., Kanda Y., Kurokawa M., Ogawa S., Oda H., Taniguchi M., Hirai H., and Chiba S. Host-residual invariant NK T cells attenuate graft-versus-host immunity. J Immunol 175 (2005) 1320
42. Hashimoto D., Asakura S., Miyake S., Yamamura T., Van Kaer L., Liu C., Tanimoto M., and Teshima T. Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J Immunol 174 (2005) 551
43. Seino K.I., Fukao K., Muramoto K., Yanagisawa K., Takada Y., Kakuta S., Iwakura Y., Van Kaer L., Takeda K., Nakayama T., Taniguchi M., Bashuda H., Yagita H., and Okumura K. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance. Proc Natl Acad Sci U S A 98 (2001) 2577
44. Jiang X., Shimaoka T., Kojo S., Harada M., Watarai H., Wakao H., Ohkohchi N., Yonehara S., Taniguchi M., and Seino K. Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 175 (2005) 2051
45. Oh K., Kim S., Park S.H., Gu H., Roopenian D., Chung D.H., Kim Y.S., and Lee D.S. Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity. J Immunol 174 (2005) 2030
46. Sonoda K.H., Taniguchi M., and Stein-Streilein J. Long-term survival of corneal allografts is dependent on intact CD1d-reactive NKT cells. J Immunol 168 (2002) 2028
47. Kiyomoto T., Ito T., Uchikoshi F., Ohkawa A., Akamaru Y., Miao G., Komoda H., Nishida T., and Matsuda H. The potent role of graft-derived NKR-P1+TCRalphabeta+ T (NKT) cells in the spontaneous acceptance of rat liver allografts. Transplantation 80 (2005) 1749
48. Yasunami Y., Kojo S., Kitamura H., Toyofuku A., Satoh M., Nakano M., Nabeyama K., Nakamura Y., Matsuoka N., Ikeda S., Tanaka M., Ono J., Nagata N., Ohara O., and Taniguchi M. Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets. J Exp Med 202 (2005) 913
49. Toyofuku A., Yasunami Y., Nabeyama K., Nakano M., Satoh M., Matsuoka N., Ono J., Nakayama T., Taniguchi M., Tanaka M., and Ikeda S. Natural killer T-cells participate in rejection of islet allografts in the liver of mice. Diabetes 55 (2006) 34
50. Levings M.K., Sangregorio R., Galbiati F., Squadrone S., de Waal Malefyt R., and Roncarolo M.G. IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 166 (2001) 5530
51. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., de Waal-Malefyt R., Coffman R.L., Hawrylowicz C.M., and O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195 (2002) 603
52. Kemper C., Chan A.C., Green J.M., Brett K.A., Murphy K.M., and Atkinson J.P. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 421 (2003) 388
53. Jonuleit H., Schmitt E., Schuler G., Knop J., and Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192 (2000) 1213
54. Battaglia M., Stabilini A., Draghici E., Gregori S., Mocchetti C., Bonifacio E., and Roncarolo M.G. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55 (2006) 40
55. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195 (2002) 695
56. Gonzalez-Rey E., Chorny A., Fernandez-Martin A., Ganea D., and Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107 (2006) 3632
57. Akiyama Y., Shirasugi N., Aramaki O., et al. Intratracheal delivery of a single major histocompatibility complex class I peptide induced prolonged survival of fully allogeneic cardiac grafts and generated regulatory cells. Hum Immunol 63 (2002) 888
58. Aramaki O., Inoue F., Takayama T., Shimazu M., Kitajima M., Ikeda Y., Okumura K., Yagita H., Shirasugi N., and Niimi M. Abstract Interleukin-10 but not transforming growth factor-beta is essential for generation and suppressor function of regulatory cells induced by intratracheal delivery of alloantigen. Transplantation 79 (2005) 568
59. Niederkorn J.Y., and Mayhew E. Phenotypic analysis of oral tolerance to alloantigens: evidence that the indirect pathway of antigen presentation is involved. Transplantation 73 (2002) 1493
60. Niimi M., Shirasugi N., Ikeda Y., and Wood K.J. Oral antigen induces allograft survival by linked suppression via the indirect pathway. Transplant Proc 33 (2001) 81
61. Liu Z., Tugulea S., Cortesini R., and Suciu-Foca N. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int Immunol 10 (1998) 775
62. Jiang S., Tugulea S., Pennesi G., Liu Z., Mulder A., Lederman S., Harris P., Cortesini R., and Suciu-Foca N. Induction of MHC-class I restricted human suppressor T cells by peptide priming in vitro. Hum Immunol 59 (1998) 690
63. Ciubotariu R., Colovai A.I., Pennesi G., Liu Z., Smith D., Berlocco P., Cortesini R., and Suciu-Foca N. Free full text specific suppression of human CD4+ Th cell responses to pig MHC antigens by CD8+CD28- regulatory T cells. J Immunol 161 (1998) 5193
64. Filaci G., Fravega M., Negrini S., Procopio F., Fenoglio D., Rizzi M., Brenci S., Contini P., Olive D., Ghio M., Setti M., Accolla R.S., Puppo F., and Indiveri F. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 65 (2004) 142
65. Manavalan J.S., Kim-Schulze S., Scotto L., Naiyer A.J., Vlad G., Colombo P.C., Marboe C., Mancini D., Cortesini R., and Suciu-Foca N. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 16 (2004) 1055
66. Baeten D., Louis S., Braud C., Braudeau C., Ballet C., Moizant F., Pallier A., Giral M., Brouard S., and Soulillou J.P. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 17 (2006) 294
67. Colovai A.I., Mirza M., Vlad G., Wang S., Ho E., Cortesini R., and Suciu-Foca N. Regulatory CD8+CD28-T cells in heart transplant recipients. Hum Immunol 64 (2003) 31
68. Ciubotariu R., Vasilescu R., Ho E., Cinti P., Cancedda C., Poli L., Late M., Liu Z., Berloco P., Cortesini R., Suciu-Foca, and Cortesini N. Detection of T suppressor cells in patients with organ allografts. Hum Immunol 62 (2001) 15
69. Sindhi R., Manavalan J.S., Magill A., Suciu-Foca N., and Zeevi A. Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28-T-suppressor cells. Hum Immunol 66 (2005) 252
70. Najafian N., Chitnis T., Salama A.D., Zhu B., Benou C., Yuan X., Clarkson M.R., Sayegh M.H., and Khoury S.J. Regulatory functions of CD8+CD28-T cells in an autoimmune disease model. J Clin Invest 112 (2003) 1037
71. Young K.J., DuTemple B., Phillips M.J., and Zhang L. Inhibition of graft-versus-host disease by double-negative regulatory T cells. J Immunol 171 (2003) 134
72. Chen W., Ford M.S., Young K.J., Cybulsky M.I., and Zhang L. Role of double-negative regulatory T cells in long-term cardiac xenograft survival. J Immunol 170 (2003) 1846
73. Young K.J., Yang L., Phillips M.J., and Zhang L. Donor-lymphocyte infusion induces transplantation tolerance by activating systemic and graft-infiltrating double-negative regulatory T cells. Blood 100 (2002) 3408
74. Chen W., Zhou D., Torrealba J.R., Waddell T.K., Grant D., and Zhang L. Donor lymphocyte infusion induces long-term donor-specific cardiac xenograft survival through activation of recipient double-negative regulatory T cells. J Immunol 175 (2005) 3409
75. Lee B.P., Mansfield E., Hsieh S.C., Hernandez-Boussard T., Chen W., Thomson C.W., Ford M.S., Bosinger S.E., Der S., Zhang Z.X., Zhang M., Kelvin D.J., Sarwal M.M., and Zhang L. Expression profiling of murine double-negative regulatory T cells suggest mechanisms for prolonged cardiac allograft survival. J Immunol 174 (2005) 4535
76. Lee B.P., Chen W., Shi H., Der S.D., Forster R., and Zhang L. CXCR5/CXCL13 interaction is important for double-negative regulatory T cell homing to cardiac allografts. J Immunol 176 (2006) 5276
77. Ford M.S., Young K.J., Zhang Z., Ohashi P.S., and Zhang L. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med 196 (2002) 261
78. Fischer K., Voelkl S., Heymann J., Przybylski G.K., Mondal K., Laumer M., Kunz-Schughart L., Schmidt C.A., Andreesen R., and Mackensen A. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8-double-negative regulatory T cells. Blood 105 (2005) 2828
79. Macian F., Garcia-Cozar F., Im S.H., Horton H.F., Byrne M.C., and Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109 (2002) 719
80. Anandasabapathy N., Ford G.S., Bloom D., Holness C., Paragas V., Seroogy C., Skrenta H., Hollenhorst M., Fathman C.G., and Soares L. GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells. Immunity 18 (2003) 535
81. Mueller D.L. E3 ubiquitin ligases as T cell anergy factors. Nat Immunol 5 (2004) 883
82. Soares L., Seroogy C., Skrenta H., Anandasabapathy N., Lovelace P., Chung C.D., Engleman E., and Fathman C.G. Two isoforms of otubain 1 regulate T cell anergy via GRAIL. Nat Immunol 5 (2004) 45
83. Jeon M.S., Atfield A., Venuprasad K., Krawczyk C., Sarao R., Elly C., Yang C., Arya S., Bachmaier K., Su L., Bouchard D., Jones R., Gronski M., Ohashi P., Wada T., Bloom D., Fathman C.G., Liu Y.C., and Penninger J.M. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21 (2004) 167
84. Safford M., Collins S., Lutz M.A., Allen A., Huang C.T., Kowalski J., Blackford A., Horton M.R., Drake C., Schwartz R.H., and Powell J.D. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat Immunol 6 (2005) 472
85. Lombardi G., Sidhu S., Batchelor R., and Lechler R. Anergic T cells as suppressor cells in vitro. Science 264 (1994) 1587
86. Frasca L., Carmichael P., Lechler R., and Lombardi G. Anergic T cells effect linked suppression. Eur J Immunol 27 (1997) 3191
87. Chai J.G., Bartok I., Chandler P., Vendetti S., Antoniou A., Dyson J., and Lechler R. Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol 29 (1999) 686
88. Bashuda H., Kimikawa M., Seino K., Kato Y., Ono F., Shimizu A., Yagita H., Teraoka S., and Okumura K. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest 115 (2005) 1896
89. Vendetti S., Chai J.G., Dyson J., Simpson E., Lombardi G., and Lechler R. Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol 165 (2000) 1175
90. Ng W.F., Duggan P.J., Ponchel F., Matarese G., Lombardi G., Edwards A.D., Isaacs J.D., and Lechler R.I. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 98 (2001) 2736
91. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., and Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 193 (2001) 1285
92. Dieckmann D., Plottner H., Berchtold S., Berger T., and Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 193 (2001) 1303
93. Levings M.K., Sangregorio R., and Roncarolo M.G. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 193 (2001) 1295
94. Modigliani Y., Coutinho A., Pereira P., Le Douarin N., Thomas-Vaslin V., Burlen-Defranoux O., Salaun J., and Bandeira A. Establishment of tissue-specific tolerance is driven by regulatory T cells selected by thymic epithelium. Eur J Immunol 26 (1996) 1807
95. Jordan M.S., Boesteanu A., Reed A.J., Petrone A.L., Holenbeck A.E., Lerman M.A., Naji A., and Caton A.J. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol 2 (2001) 301
96. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057
97. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4 (2003) 330
98. Khattri R., Cox T., Yasayko S.A., and Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 4 (2003) 337
99. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., and Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20
100. Watanabe N., Wang Y.H., Lee H.K., Ito T., Wang Y.H., Cao W., and Liu Y.J. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436 (2005) 1181
101. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., and Wahl S.M. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 (2003) 1875
102. Marie J.C., Letterio J.J., Gavin M., and Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201 (2005) 1061
103. Fontenot J.D., Rasmussen J.P., Gavin M.A., and Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6 (2005) 1142
104. D'Cruz L.M., and Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 6 (2005) 1152
105. Setoguchi R., Hori S., Takahashi T., and Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201 (2005) 723
106. Bayer A.L., Yu A., Adeegbe D., and Malek T.R. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 201 (2005) 769
107. Thornton A.M., and Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287
108. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., Kroemer G., Martin F., Chauffert B., and Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 202 (2005) 919
109. Peng Y., Laouar Y., Li M.O., Green E.A., and Flavell R.A. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci 101 (2004) 4572
110. Piccirillo C.A., and Shevach E.M. Control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 167 (2001) 1137
111. Smyth M.J., Teng M.W., Swann J., Kyparissoudis K., Godfrey D.I., and Hayakawa Y. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176 (2006) 1582
112. Ghiringhelli F., Menard C., Terme M., Flament C., Taieb J., Chaput N., Puig P.E., Novault S., Escudier B., Vivier E., Lecesne A., Robert C., Blay J.Y., Bernard J., Caillat-Zucman S., Freitas A., Tursz T., Wagner-Ballon O., Capron C., Vainchencker W., Martin F., and Zitvogel L. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202 (2005) 1075
113. Zhao D.M., Thornton A.M., Dipaolo R.J., and Shevach E.M. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107 (2006) 3925
114. Thornton A.M., and Shevach E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 164 (2000) 183
115. Nakamura K., Kitani A., and Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194 (2001) 629
116. Huang C.T., Workman C.J., Flies D., Pan X., Marson A.L., Zhou G., Hipkiss E.L., Ravi S., Kowalski J., Levitsky H.I., Powell J.D., Pardoll D.M., Drake C.G., and Vignali D.A. Role of LAG-3 in regulatory T cells. Immunity 21 (2004) 503
117. McHugh R.S., Whitters M.J., Piccirillo C.A., Young D.A., Shevach E.M., Collins M., and Byrne M.C. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 (2002) 311
118. Shimizu J., Yamazaki S., Takahashi T., Ishida Y., and Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3 (2002) 135
119. Mellor A.L., and Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4 (2004) 762
120. Gondek D.C., Lu L.F., Quezada S.A., Sakaguchi S., and Noelle R.J. Contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 174 (2005) 1783
121. Grossman W.J., Verbsky J.W., Barchet W., Colonna M., Atkinson J.P., and Ley T.J. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21 (2004) 589
122. Liu H., Komai-Koma M., Xu D., and Liew F.Y. Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells. Proc Natl Acad Sci 103 (2006) 7048
123. Yang Y., Huang C.T., Huang X., and Pardoll D.M. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 5 (2004) 508
124. Pasare C., and Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299 (2003) 1033
125. Jiang S., Game D.S., Davies D., Lombardi G., and Lechler R.I. Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4+CD25+ regulatory T cells?. Eur J Immunol 35 (2005) 1193
126. Liu R., La Cava A., Bai X.F., Jee Y., Price M., Campagnolo D.I., Christadoss P., Vollmer T.L., Van Kaer L., and Shi F.D. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 175 (2005) 7898
127. Yang J.Q., Saxena V., Xu H., Van Kaer L., Wang C.R., and Singh R.R. Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 171 (2003) 4439
128. Nakamura T., Sonoda K.H., Faunce D.E., Gumperz J., Yamamura T., Miyake S., and Stein-Streilein J. CD4+ NKT cells, but not conventional CD4+ T cells, are required to generate efferent CD8+ T regulatory cells following antigen inoculation in an immune-privileged site. J Immunol 171 (2003) 1266
129. Roelofs-Haarhuis K., Wu X., and Gleichmann E. Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells. J Immunol 173 (2004) 1043
130. Kim H.J., Hwang S.J., Kim B.K., Jung K.C., and Chung D.H. NKT cells play critical roles in the induction of oral tolerance by inducing regulatory T cells producing IL-10 and transforming growth factor beta, and by clonally deleting antigen-specific T cells. Immunology 118 (2006) 101
131. Jiang S., Camara N., Lomabardi G., and Lechler R.I. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 102 (2003) 2180
132. Golshyan D, Jiang S, Tsang J, Garin M, Mottet C, Lechler RI: In-vitro expanded donor alloantigen-specific CD4+CD25+ regulatory T cells induce experimental transplantation tolerance. Blood (in press).
133. Masteller E.L., Warner M.R., Tang Q., Tarbell K.V., McDevitt H., and Bluestone J.A. Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J Immunol 175 (2005) 3053
134. Tang Q., Henriksen K.J., Bi M., Finger E.B., Szot G., Ye J., Masteller E.L., McDevitt H., Bonyhadi M., and Bluestone J.A. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199 (2004) 1455
135. Tarbell K.V., Yamazaki S., Olson K., Toy P., and Steinman R.M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med 199 (2004) 1467
136. Mekala D.J., and Geiger T.L. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 105 (2005) 2090
137. Mekala D.J., Alli R.S., and Geiger T.L. IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Proc Natl Acad Sci 102 (2005) 11817
138. Trenado A., Sudres M., Tang Q., Maury S., Charlotte F., Gregoire S., Bonyhadi M., Klatzmann D., Salomon B.L., and Cohen J.L. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 176 (2006) 1266
139. Taylor P.A., Panoskaltsis-Mortari A., Swedin J.M., Lucas P.J., Gress R.E., Levine B.L., June C.H., Serody J.S., and Blazar B.R. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 104 (2004) 3804
140. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., and Negrin R.S. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9 (2003) 1144
141. Godfrey W.R., Ge Y.G., Spoden D.J., Levine B.L., June C.H., Blazar B.R., and Porter S.B. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104 (2004) 453
142. Hoffmann P., Eder R., Kunz-Schughart L.A., Andreesen R., and Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 104 (2004) 895
143. Bluestone J.A. Regulatory T-cell therapy: is it ready for the clinic?. Nat Rev Immunol 5 (2005) 343
144. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., de St Groth B.F., Clayberger C., Soper D.M., Ziegler S.F., and Bluestone J.A. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203 (2006) 1701
145. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., Kelleher A., and de St Groth B.F. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203 (2006) 1693